Abstract: A duty cycle correction method and a duty cycle correction apparatus, adapted for correcting a duty cycle of a clock signal by using a duty cycle adjuster in a high-capacity and high-performance semiconductor product such as a 3D NAND flash, are provided. In the method, the duty cycle is adjusted and input to data pads to generate data signals, wherein the data pads are divided into at least two groups and defined by data patterns that are inverse to each other; DC voltages of the data signals of a first group of data pads are detected to generate a first average DC voltage, and DC voltages of the data signals of a second group of data pads are detected to generate a second average DC voltage, the aforementioned average DC voltages are compared, and the duty cycle adjuster is controlled to adjust the duty cycle of the clock signal.

Abstract: A calibration apparatus of a memory device and a calibration method thereof are provided. The memory device is a 3D NAND flash with high capacity and high performance. The calibration apparatus includes an impedance, a strong-arm comparator, a logic circuit, and a calibration controller. The impedance is configured to generate a comparison voltage. The strong-arm comparator includes a differential input pair and a latch. The differential input pair compares a reference voltage and the comparison voltage to produce a comparison result. The latch latches the comparison result and generates a latch signal and an inverted latch signal accordingly. The logic circuit generates a comparison result signal according to the latch signal and the inverted latch signal. The calibration controller implements an impedance calibration in the memory device according to the comparison result signal.

Abstract: Systems, methods, circuits, and apparatus for managing signal transfers in semiconductor devices are provided. In one aspect, an integrated circuit includes: one or more target units each configured to receive a signal and a plurality of inverting units arranged on signal paths to the one or more target units. For each of the one or more target units, one or more corresponding inverting units of the plurality of inverting units are configured to invert the signal multiple times along a corresponding signal path to the target unit to cause a signal width of the inverted signal received by the target unit to be substantially identical to a signal width of the signal.

Abstract: Systems, methods, circuits, and apparatus for managing signal transfers in semiconductor devices are provided. In one aspect, an integrated circuit includes: one or more target units each configured to receive a signal and a plurality of inverting units arranged on signal paths to the one or more target units. For each of the one or more target units, one or more corresponding inverting units of the plurality of inverting units are configured to invert the signal multiple times along a corresponding signal path to the target unit to cause a signal width of the inverted signal received by the target unit to be substantially identical to a signal width of the signal.

Abstract: The present invention provides a method comprising (a) obtaining a single cell gene expression profile comprising gene expression measurements for a set of genes, for a plurality of cells, and a single cell protein expression profile comprising protein expression measurements for two or more proteins, for the plurality of cells; (b) using the single cell protein expression profiles and an unsupervised learning method to assign a cell type class to at least some of the plurality of cells; and(d) applying a feature selection process to the single gene expression profiles to identify genes in the single cell gene expression profiles that are predictive of the cell type classes assigned in step (b), wherein the genes identified in step (d) form a predictor set of genes for predicting the cell type of one or more cells.

Abstract: Medical device systems and methods are disclosed herein for assessing motor symptoms in Parkinson's disease patients through passively and/or actively acquired sensor data of motor behaviors and generating motor system assessments. Passive movement data and/or active motor performance data collected from Parkinson's disease patients is representative of EQ-5D-5L, PDQ-39, and/or MDS-UPDRS health status measurement data to more accurately predict quality of life, health status, and disease severity of Parkinson's disease patients. The generated motor system assessment may be used to provide neurologists and other health professionals with more accurate treatment recommendations and disease management protocols rather than using patient surveys alone.

Abstract: Aspects of the disclosure relate to mobile-optimized software tools that may be deployed and used to measure spatial working memory across diverse clinical trial populations. For example, some aspects describe computational optimization and participatory design of a novel spatial working memory task for clinical trials relating to autism spectrum disorders (ASD) or other neurological conditions (e.g., Alzheimer's disease). Software tools as described herein may be used for measuring treatment effects on spatial working memory and/or provide treatments to improve a patient's spatial working memory. Digital biomarkers may be generated for each patient based on the patient's spatial working memory.

Abstract: The invention provides methods of monitoring differential gene expression of pharmacodynamic (PD) biomarkers in patients treated with Lysine Demethylase 1 (LSD 1) inhibitors and methods of determining the sensitivity of a cell to an LSD 1 inhibitor by measuring PD biomarkers.

Abstract: The present application discloses a method to predict responsiveness of a patient, with cancer, to treatment with LSD1 inhibitors, said method comprising measuring mRNA expression levels of one or more genes selected from the list of ASCL1, DDC, CEACAM6, LRRIQ4, NR0B2, GRP, CEACAM5, SOX21, OR51E2, SEC11C, BAALC, CCDC40, RAB3B, RGS17, ABCE1, ETS2, CCDC154, SPAG6, PON1, TMEM176A, C1orf127, IGF2BP2, IGFBP5, FAM84A, FOXA2, HOXA10, NCAM1, NCAM2, NEUROD1, KRT8, ENO2, AVP, OXT, SYP, CHGA, CHGB, BCL2 and MYC.

Abstract: The present invention is directed to compositions and methods for the independent and unconstrained identification of attractor metagenes as surrogates of pure biomolecular events as well as the use of such attractor metagenes in performing medical diagnosis, prognosis, and developing appropriate therapeutic regimes.

Abstract: The present invention provides compounds having estrogenic activity selected from the group consisting of RRR-?-tocopherol, hydro-Q9 chromene, coenzyme Q9, cycloartane, 1-Feruloyl glycerol, ?-tocopherol-9, and analogues thereof. The compounds of the present invention activate ER? and ER?, and express high estrogenic activity.

Abstract: The present invention provides compounds having estrogenic activity selected from the group consisting of RRR-?-tocopherol, hydro-Q9 chromene, coenzyme Q9, cycloartane, 1-Feruloyl glycerol, ?-tocopherol-9, and analogues thereof. The compounds of the present invention activate ER? and ER?, and express high estrogenic activity.